{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-253709","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-06-02T20:45:51+00:00","discovered_at":"2026-06-02T20:47:17.305438+00:00","generated_at":"2026-06-02T20:47:30.253845+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced","bullets":["Resignations of directors Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen effective May 29, 2026.","Sumita Ray appointed Chief Legal & Compliance Officer and Corporate Secretary on June 1, 2026.","Michael Meluzio appointed VP, Principal Accounting Officer on June 1, 2026.","Daniel Camardo and Viola Meehan appointed as directors on May 30, 2026; board reduced from seven to five."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253709","json":"https://secwatch.observer/filing/0001193125-26-253709.json","markdown":"https://secwatch.observer/filing/0001193125-26-253709.md","text":"https://secwatch.observer/filing/0001193125-26-253709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:47:30.253845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0315e9ae30","claim":"Patrick Verheyen departed as member of the Board of Directors at Cue Biopharma, Inc..","evidence_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"2ca23b462b","claim":"Peter Kiener departed as member of the Board of Directors at Cue Biopharma, Inc..","evidence_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"2e4f2ed2c4","claim":"Daniel Camardo was appointed as director at Cue Biopharma, Inc..","evidence_excerpt":"On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"573c096941","claim":"Viola Meehan was appointed as director at Cue Biopharma, Inc..","evidence_excerpt":"On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"7d66bf3983","claim":"Michael Meluzio was appointed as Vice President, Principal Accounting Officer at Cue Biopharma, Inc..","evidence_excerpt":"On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"ab86580cc7","claim":"Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma, Inc..","evidence_excerpt":"On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"b26c64a588","claim":"Colin Sandercock changed role as Senior Vice President, Intellectual Property at Cue Biopharma, Inc..","evidence_excerpt":"Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":0.9},{"claim_id":"d9e64a264b","claim":"Jill Broadfoot departed as member of the Board of Directors at Cue Biopharma, Inc..","evidence_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0},{"claim_id":"f71a876bae","claim":"Frank Morich departed as member of the Board of Directors at Cue Biopharma, Inc..","evidence_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","confidence":1.0}],"comparable_filings":[{"accession":"0001129928-26-000039","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-06-02T13:02:48+00:00","headline":"Oncolytics appoints Steve Glover to board, promotes John McAdory to COO","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000039","json":"https://secwatch.observer/filing/0001129928-26-000039.json","markdown":"https://secwatch.observer/filing/0001129928-26-000039.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/0001129928-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/oncy-20260602.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"appointed John McAdory as Chief Operating Officer of the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/0001129928-26-000039-index.htm"}},{"accession":"0001628280-26-039461","ticker":"GRAL","company_name":"GRAIL, Inc.","filed_at":"2026-06-01T20:07:27+00:00","headline":"GRAIL appoints Joshua Ofman as CEO with amended compensation and severance","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039461","json":"https://secwatch.observer/filing/0001628280-26-039461.json","markdown":"https://secwatch.observer/filing/0001628280-26-039461.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/gral-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm"}},{"accession":"0001193125-26-248230","ticker":"LNSR","company_name":"LENSAR, Inc.","filed_at":"2026-05-29T20:05:15+00:00","headline":"LENSAR appoints Michael A. Rossi as Interim CFO; annual meeting set for Aug 4, 2026","event_type":"leadership","sec_items":["5.02","5.08","8.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-248230","json":"https://secwatch.observer/filing/0001193125-26-248230.json","markdown":"https://secwatch.observer/filing/0001193125-26-248230.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000119312526248230/0001193125-26-248230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000119312526248230/lnsr-20260525.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1320350/000119312526248230/0001193125-26-248230-index.htm"}},{"accession":"0001193125-26-253858","ticker":"BTMD","company_name":"biote Corp.","filed_at":"2026-06-02T21:17:02+00:00","headline":"Biote CEO Christensen resigns; CFO Peterson named Interim CEO; Marc Beer Executive Chairman; FY2026 guidance reaffirmed","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253858","json":"https://secwatch.observer/filing/0001193125-26-253858.json","markdown":"https://secwatch.observer/filing/0001193125-26-253858.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526253858/0001193125-26-253858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526253858/d215108d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526253858/0001193125-26-253858-index.htm"}},{"accession":"0001193125-26-253839","ticker":"NUE","company_name":"NUCOR CORP","filed_at":"2026-06-02T21:11:31+00:00","headline":"Nucor EVP David Sumoski to retire June 13, 2026; receives $308,851/month for 24 months","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253839","json":"https://secwatch.observer/filing/0001193125-26-253839.json","markdown":"https://secwatch.observer/filing/0001193125-26-253839.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/73309/000119312526253839/0001193125-26-253839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/73309/000119312526253839/d112329d8ka.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"On May 28, 2026, the Company and Mr. Sumoski entered into a Retirement, Separation, Waiver and Release Agreement (the “Retirement Agreement”) in connection with Mr. Sumoski’s retirement from employment with the Company, effective June 13, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/73309/000119312526253839/0001193125-26-253839-index.htm"}},{"accession":"0001193125-26-253829","ticker":"BSTT","company_name":"Blackstone Real Estate Income Trust, Inc.","filed_at":"2026-06-02T21:08:19+00:00","headline":"Zaneta Koplewicz resigns as Co-President and Director of Blackstone Real Estate Income Trust","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253829","json":"https://secwatch.observer/filing/0001193125-26-253829.json","markdown":"https://secwatch.observer/filing/0001193125-26-253829.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662972/000119312526253829/0001193125-26-253829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662972/000119312526253829/d41828d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"On June 2, 2026, Zaneta Koplewicz resigned from Blackstone Real Estate Income Trust, Inc. (the “Company”) as Co-President, Head of Shareholder Relations and as a member of the Company’s Board of Directors (the “Board”), effective June 24, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1662972/000119312526253829/0001193125-26-253829-index.htm"}},{"accession":"0001731122-26-000806","ticker":"VWAV","company_name":"VisionWave Holdings, Inc.","filed_at":"2026-06-02T21:01:25+00:00","headline":"VisionWave appoints Einav Eliraz as CFO of subsidiary VisionWave IL; grants 500K share options","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000806","json":"https://secwatch.observer/filing/0001731122-26-000806.json","markdown":"https://secwatch.observer/filing/0001731122-26-000806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000806/0001731122-26-000806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000806/e7681_8-k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"On June 1, 2026, VisionWave IL Ltd. (“VisionWave IL”), a wholly-owned subsidiary of VisionWave Holdings, Inc. (the “Company”), entered into an Employment Agreement with Mr. Einav Eliraz pursuant to which Mr. Eliraz was appointed Chief Financial Officer (“CFO”) of VisionWave IL, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2038439/000173112226000806/0001731122-26-000806-index.htm"}},{"accession":"0001868419-26-000039","ticker":"CYCU","company_name":"Cycurion, Inc.","filed_at":"2026-06-02T20:43:53+00:00","headline":"Cycurion appoints Ana Garcia as CFO; Alvin McCoy III transitions to strategic advisor","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001868419-26-000039","json":"https://secwatch.observer/filing/0001868419-26-000039.json","markdown":"https://secwatch.observer/filing/0001868419-26-000039.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868419/000186841926000039/0001868419-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868419/000186841926000039/cycu-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm","comparable_excerpt":"the Company also announced the appointment of Ana Garcia as its new Chief Financial Officer, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1868419/000186841926000039/0001868419-26-000039-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}